Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01466036 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT01466036 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 61 participants.
The verdict
NCT01466036, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
Cabozantinib works by blocking the growth of new blood vessels that feed a tumor. In addition to blocking the formation of new blood cells in tumors, cabozantinib also blocks pathways that may be responsible for allowing cancers cells to become resistant to other "anti-angiogenic" drugs. Cabozantinib has been studied or is being study in research studies as a possible treatment for various types of cancer, including prostate cancer, brain cancer, thyroid cancer, lung cancer, and kidney cancer. In this research study, the investigators wish to learn if cabozantinib is effective in treating patients with pancreatic neuroendocrine and carcinoid tumors.
Interventions
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2012-07 |
| Est. Completion | 2023-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01466036
The ClinicalTrials.gov registry entry for NCT01466036 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cabozantinib is the first listed.
NCT01466036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01466036 about?
NCT01466036 is a clinical study titled "Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors". Cabozantinib works by blocking the growth of new blood vessels that feed a tumor. In addition to blocking the formation of new blood cells in tumors, cabozantinib also blocks pathways that may be responsible for allowing cancers cells to become resistant to other "anti-angiogenic" drugs. Cabozantini...
What is the current status of trial NCT01466036?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2012-07. Estimated completion is 2023-12.
What interventions are being tested in trial NCT01466036?
The interventions under investigation include: Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT01466036?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.